Working… Menu

Study Evaluating the Pharmacokinetic Profile of RhuDex® in a Tablet Formulation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00704119
Recruitment Status : Terminated (Following an SAE, study was put on hold. After performing preclinical follow-up studies, volunteers were no longer available for continuation.)
First Posted : June 24, 2008
Last Update Posted : March 24, 2010
Information provided by:

Brief Summary:

RhuDex® (code number AV1142742) is a novel, orally bioavailable, low molecular weight modulator of co-stimulation of T lymphocytes. RhuDex® binds to the protein CD80 (also known as B7-1) on the surface of antigen-presenting cells and inhibits its interaction with CD28 (but not with CTLA-4) presented by CD4+ T lymphocytes.

RhuDex® is being developed for the treatment of rheumatoid arthritis. To improve oral bioavailability, the study drug has to be co-administered with an alkaline buffer that increases gastric pH values. In previous in vitro and phase I studies, meglumine has been identified as the most effective buffer. Study CT 5002 is designed to evaluate the bioavailability of four increasing doses of RhuDex®, combined with a fixed amount of meglumine using a tablet formulation, under fed and fasted conditions as well as with co-administration of the proton pump inhibitor pantoprazole. Furthermore, dose/plasma concentration proportionality for single dosing and accumulation effects for repeat dosing of RhuDex® will be evaluated.

Condition or disease Intervention/treatment Phase
Pharmacokinetics Drug: RhuDex® Phase 1

Detailed Description:

This is an open-label, non-randomized, monocentric Phase I study to evaluate the pharmacokinetic profile of single-dosed and repeat-dosed RhuDex® using a tablet formulation as well as to assess the effect of food and the effect with co-administration of a proton pump inhibitor on the bioavailability of RhuDex®.

12 healthy male subjects will receive study medication in 8 different treatment periods in 4 subsequent steps A, B, C and D.

Within steps A and B, the subjects will receive different treatments (4 in A and 2 in B), sequentially. There will be a wash-out period of at least 4 days between each of the 8 different treatments/treatment periods of steps A, B, C and D.

In Step A, each subject will receive increasing doses of RhuDex® in 4 subsequent treatments. In Step B, each subject will receive 2 different doses of RhuDex® preceded by pantoprazole intake, in 2 subsequent treatments, and in Step C the RhuDex® dosing will be preceded by a standardized high-fat, high-calorie meal. In Step D, RhuDex® will be administered twice daily for 7 days.

For assessing the pharmacokinetic profile of RhuDex® in steps A, B and C, blood samples will be collected prior to and at different intervals after RhuDex® administration. In step D, blood samples will be collected on Days 1, 2, 4 and 7. Cmin, Cmax, tmax, t½ term, CL/F, AUC(0-t), and AUC(0-∞) of RhuDex® will be analyzed.

Safety will be evaluated by regular observation and documentation of AEs, vital signs, physical examination, ECG, and laboratory parameters.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: CT 5002 An Open-label, Non-randomized, Monocentric Phase I Study Evaluating the Pharmacokinetic Profile of RhuDex® Using a Tablet Formulation
Study Start Date : May 2008
Actual Primary Completion Date : July 2008
Actual Study Completion Date : August 2008

Intervention Details:
  • Drug: RhuDex®
    • Treatment A.1: 31.65 mg RhuDex® once N=12
    • Treatment A.2: 63.33 mg RhuDex® once N=12
    • Treatment A.3: 126.63 mg RhuDex® once N=12
    • Treatment A.4: 253.26 mg RhuDex® once N=12
    • Treatment B.1: 31.65 mg RhuDex® once N=12
    • Treatment B.2: selected dose of RhuDex® once N=12
    • Treatment C: selected dose of RhuDex® once N=12
    • Treatment D: selected dose of RhuDex® twice daily for 6 days N=12
    Other Name: AV1142742

Primary Outcome Measures :
  1. To assess the relationship between the dose of RhuDex® administered and the plasma concentrations achieved following single and repeated doses under fed and/or fasted conditions and with/without administration of pantoprazole [ Time Frame: 24 -96h pharmakokinetic laboratory values ]

Secondary Outcome Measures :
  1. To gain further safety and tolerability data of RhuDex® [ Time Frame: during treatment phase and 28 days afterwards ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy male subjects between 18 and 60 years at the time of enrolment
  2. Subjects who are sexually active must use adequate contraception for the duration of the study from screening until 12 weeks after the last dose.
  3. BMI between 18.5 and 29.9 kg/m²
  4. Written informed consent
  5. Ability to comply with the requirements of the study

Exclusion Criteria:

  1. Acute infection at time of enrolment
  2. History of chronic inflammation, chronic infection, other chronic disease, autoimmune disorders (e.g. diabetes mellitus) or cancer
  3. Clinically significant abnormal ECG
  4. Clinically significant abnormal laboratory values (especially in terms of liver or renal insufficiency)
  5. Clinically significant physical findings
  6. Major surgery within the last 4 weeks prior to enrolment
  7. Organ allograft recipient
  8. Concomitant or planned treatment which would interfere with study results
  9. Any systemic medical treatment, including over the counter products and dietary supplements such as iodine, fluoride or vitamins, within one week before and during the study course
  10. Known allergy against any ingredient of the study medication, meglumine, pantoprazole or bovine milk
  11. Participation in an investigational trial within 12 weeks prior to enrolment
  12. Systemic intake of immunosuppressive or immunomodulatory medication or vaccination within 30 days prior to enrolment and for the whole study duration
  13. Blood loss exceeding 450 mL (including blood donations) within 12 weeks prior to enrolment into the study.
  14. Medical history of alcohol or drug abuse within the last 2 years or alcohol consumption greater than 21 units per week.
  15. A positive alcohol breath test
  16. A positive urine drug screen
  17. Smokers who smoke > 5 cigarettes or 5 cigars per day
  18. Presence of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab) or HIV-1 or HIV-2 antibodies at screening
  19. Subject whose partner is pregnant or lactating

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00704119

Layout table for location information
United Kingdom
Charles River Clinical Services Edinburgh Ltd
Edinburgh, Scotland, United Kingdom, EH14 4AP
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Stuart Mair, MBChB, DROCG,DCPSA Syneos Health

Layout table for additonal information
Responsible Party: Prof. HodaTawfik, Clinical Project Manager, MediGene AG Identifier: NCT00704119     History of Changes
Other Study ID Numbers: CT 5002
First Posted: June 24, 2008    Key Record Dates
Last Update Posted: March 24, 2010
Last Verified: March 2010
Keywords provided by MediGene:
pharmacokinetic study